MACOP-B treatment in children and adolescents with advanced diffuse large-cell non-Hodgkin's lymphoma

Victor M. Santana, Minnie Abromowitch, John T. Sandlund, Fred G. Behm, Gregory D. Ayers, Paula K. Roberson, Ching Hon Pui

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


From 1986 through 1990, 13 previously untreated pediatric patients with advanced diffuse large-cell non-Hodgkin's lymphoma (LC-NHL) were treated with a 12-week MACOP-B regimen at St Jude Children's Research Hospital. Although 12 patients (92%) achieved a complete response, and one had a partial response, the 2-year event-free survival was only 54 ± 15% (SE). Seven patients remain in continuous complete remission it a median of 40 months after therapy (range 23-57 months). Relapses occurred at sites of initial involvement in five patients it a median of 3.0 months after remission (range 1.2-8.5 months). Salvage therapy with radiation, and high-dose chemotherapy and bone marrow transplantation produced four durable second remissions. The 2-year overall survival for the entire group is 84 ± 10% (SE). The 12-week MACOP-B regimen proved feasible in an ambulatory clinic setting with only minimal toxicity. We found that MACOP-B is an effective and tolerable treatment for pediatric patients with LC-NHL but did not provide improved survival over that of a similar group of children treated in previous trials at this institution.

Original languageEnglish (US)
Pages (from-to)187-191
Number of pages5
Issue number2
StatePublished - Feb 1993
Externally publishedYes

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'MACOP-B treatment in children and adolescents with advanced diffuse large-cell non-Hodgkin's lymphoma'. Together they form a unique fingerprint.

Cite this